FAIFX | LMCJX | FAIFX / LMCJX | |
Total Expense Ratio | 0.36 | 1.23 | 29% |
Annual Report Gross Expense Ratio | 0.36 | 1.38 | 26% |
Fund Existence | 5 years | 12 years | - |
Gain YTD | 13.434 | 9.684 | 139% |
Front Load | N/A | 6% | - |
Min. Initial Investment | 250 | 1000 | 25% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 137B | 180M | 76,111% |
Annual Yield % from dividends | 3.79 | 4.38 | 87% |
Returns for 1 year | 11.79 | 21.50 | 55% |
Returns for 3 years | 32.81 | 61.70 | 53% |
Returns for 5 years | N/A | 83.70 | - |
Returns for 10 years | N/A | 95.13 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FBDIX | 140.36 | 2.87 | +2.09% |
Franklin Biotechnology Discovery A | |||
PRAFX | 16.49 | 0.15 | +0.92% |
T. Rowe Price Real Assets | |||
BRMIX | 16.14 | 0.04 | +0.25% |
iShares Russell Mid-Cap Index Instl | |||
EIRAX | 15.42 | 0.01 | +0.06% |
Eaton Vance All Asset Strategy I | |||
GTLSX | 14.32 | -0.05 | -0.35% |
Glenmede Long/Short Eq Ptf Instl Shrs |